9
Table 1. Breast Cancer Biomarkers to Guide Adjuvant
Therapy Newly Disagnosed
Test
ER-positive,
HER2-negative
(node-negative)
ER-positive,
HER2-negative
(node-positive)
HER2-positive or
triple-negative (TN)
Oncotype DX Yes
Yes
b
No
MammaPrint
Yes
a
Yes
a
No
Endopredict
Yes
b
Yes
b
No
Prosigna
Yes
b
No No
Mammostrat No No No
Ki67
Yes
c
Yes
d
No
IHC4
Yes
e
Yes
e
No
uPA and PAI-1 Yes
BCI
f
Yes No No
CTS5
f
No No
TILs No No No
PD-L1 No
CTC No
ctDNA No
a
Only if high risk, >50 years of age with ≤3 positive nodes.
b
Only if postmenopausal with ≤3 positive nodes.
c
Only if postmenopausal and ≤2 weeks aer IA therapy.
d
If high risk and Ki67 score ≥20% (See text).
e
Only if ≤3 positive nodes.
f
BCI and CTS5 may be used under certain conditions to guide extended endocrine therapy
decisions. (See text)
